{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:39:07Z","timestamp":1761237547975},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1007\/s12029-007-9007-6","type":"journal-article","created":{"date-parts":[[2008,6,17]],"date-time":"2008-06-17T09:24:58Z","timestamp":1213694698000},"page":"10-14","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of KW-2189, a DNA Minor Groove-Binding Agent, in Patients with Hepatocellular Carcinoma: A North Central Cancer Treatment Group (NCCTG) Phase II Clinical Trial"],"prefix":"10.1007","volume":"38","author":[{"given":"Steven R.","family":"Alberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera J.","family":"Suman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry C.","family":"Pitot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Camoriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,3]]},"reference":[{"key":"9007_CR1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-129-8-199810150-00013","volume":"129","author":"E Mor","year":"1998","unstructured":"Mor E, Kaspa RT, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med. 1998;129:643\u201353.","journal-title":"Ann Intern Med."},{"key":"9007_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1023\/A:1008285123736","volume":"8","author":"RG Simonetti","year":"1997","unstructured":"Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997;8:117\u201336.","journal-title":"Ann Oncol."},{"key":"9007_CR3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.7164\/antibiotics.44.1045","volume":"44","author":"M Ichimura","year":"1991","unstructured":"Ichimura M, Ogawa T, Katsumata S, Takahashi K-I, Takahashi I, Nakano H. Duocarmycins, new antitumor antibiotics produced by Streptomyces; producing organisms and improved production. J Antibiotics. 1991;44:1045\u201353.","journal-title":"J Antibiotics."},{"key":"9007_CR4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.7164\/antibiotics.43.1037","volume":"43","author":"M Ichimura","year":"1990","unstructured":"Ichimura M, Ogawa T, Takahashi K-I, Kobayashi E, Kawamoto I, Yasuzawa T, et al. Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp. J Antibiotics. 1990;43:1037\u20138.","journal-title":"J Antibiotics."},{"key":"9007_CR5","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.7164\/antibiotics.42.1299","volume":"42","author":"T Ogawa","year":"1989","unstructured":"Ogawa T, Ichimura M, Katsumata S, Morimoto M, Takahashi K. New antitumor antibiotics, duocarmycins B1 and B2. J Antibiotics. 1989;42:1299\u2013301.","journal-title":"J Antibiotics."},{"key":"9007_CR6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.7164\/antibiotics.41.1915","volume":"41","author":"I Takahashi","year":"1988","unstructured":"Takahashi I, Takahashi K-I, Ichimura M, Morimoto M, Asano K, Kawamoto I, et al. Duocarmycin A, a new antitumor antibiotic from Streptomyces. J Antibiotics. 1988;41:1915\u20137.","journal-title":"J Antibiotics."},{"key":"9007_CR7","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1073\/pnas.92.9.3642","volume":"92","author":"DL Boger","year":"1995","unstructured":"Boger DL, Johnson DS. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc Natl Acad Sci USA. 1995;92:3642\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"9007_CR8","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1349-7006.1994.tb02944.x","volume":"85","author":"A Okamoto","year":"1994","unstructured":"Okamoto A, Asai A, Saito H, Okabe M, Gomi K. Differential effect of duocarmycin A and its novel derivative DU-86 on DNA strand breaks in HeLa S3 cells. Jpn J Cancer Res. 1994;85:1304\u201311.","journal-title":"Jpn J Cancer Res."},{"key":"9007_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.6494915","volume":"226","author":"LH Hurley","year":"1984","unstructured":"Hurley LH, Reynolds VL, Swenson DH, Petzold GL, Scahill TA. Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science. 1984;226:843\u20134.","journal-title":"Science."},{"key":"9007_CR10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1248\/cpb.43.378","volume":"43","author":"T Yasuzawa","year":"1995","unstructured":"Yasuzawa T, Muroi K-I, Ichimura M, Takahashi I, Ogawa T, Takahashi K, et al. Duocarmycins, potent antitumor antibiotics produced by Steptomyces sp. structures and chemistry. Chem Pharm Bull. 1995;43:378\u201391.","journal-title":"Chem Pharm Bull."},{"key":"9007_CR11","first-page":"2404","volume":"54","author":"E Kobayashi","year":"1994","unstructured":"Kobayashi E, Okamoto A, Asada M, Okabe M, Nagamura S, Asai A, et al. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res. 1994;54:2404\u201310.","journal-title":"Cancer Res."},{"key":"9007_CR12","first-page":"109","volume":"48","author":"EG Adams","year":"1988","unstructured":"Adams EG, Badiner GJ, Bhuyan BK. Effects of U-71,184 and several other CC-1065 analogues on cell survival and cell cycle of Chinese hamster ovary cells. Cancer Res. 1988;48:109\u201316.","journal-title":"Cancer Res."},{"key":"9007_CR13","first-page":"2111","volume":"4","author":"SR Alberts","year":"1998","unstructured":"Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, et al. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin Cancer Res. 1998;4:2111\u20137.","journal-title":"Clin Cancer Res."},{"key":"9007_CR14","first-page":"A1138","volume":"37","author":"J Abbruzzese","year":"1996","unstructured":"Abbruzzese J, Madden T, Newman R. Phase I clinical and pharmacokinetic trial of KW2189 in patients with solid tumors (meeting abstract). Proc Annu Meet Am Assoc Cancer Res. 1996;37:A1138.","journal-title":"Proc Annu Meet Am Assoc Cancer Res."},{"key":"9007_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143\u201351.","journal-title":"Biometrics."},{"key":"9007_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2307\/2532095","volume":"46","author":"T Therneau","year":"1990","unstructured":"Therneau T, Weiand H, Chang M. Optimal designs for a grouped sequential binomial trial. Biometrics. 1990;46:771\u201381.","journal-title":"Biometrics."},{"key":"9007_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/00001813-199810000-00006","volume":"9","author":"M Cristofanilli","year":"1998","unstructured":"Cristofanilli M, Bryan WJ, Miller LL, Chang AY, Gradishar WJ, Kufe DW, et al. Phase II study of adozelesin in untreated metastatic breast cancer. Anti-Cancer Drugs. 1998;9:779\u201382.","journal-title":"Anti-Cancer Drugs."},{"key":"9007_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/00001813-199707000-00006","volume":"8","author":"HA Burris","year":"1997","unstructured":"Burris HA, Dieras VC, Tunca M, Earhart RH, Eckardt JR, Rodriguez GI, et al. Phase I study with the DNA sequence-specific agent adozelesin. Anti-Cancer Drugs. 1997;8:588\u201396.","journal-title":"Anti-Cancer Drugs."},{"key":"9007_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF00873138","volume":"13","author":"BJ Foster","year":"1996","unstructured":"Foster BJ, LoRusso PM, Poplin E, Zalupski M, Valdivieso M, Wozniak A, et al. Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks. Invest New Drugs. 1996;13:321\u20136.","journal-title":"Invest New Drugs."},{"key":"9007_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/00001813-199402000-00002","volume":"5","author":"GJ Shamdas","year":"1994","unstructured":"Shamdas GJ, Alberts DS, Modiano M, Wiggins C, Power J, Kasunic DA, et al. Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anti-Cancer Drugs. 1994;5:10\u20134.","journal-title":"Anti-Cancer Drugs."},{"key":"9007_CR21","first-page":"712","volume":"8","author":"HC Pitot","year":"2002","unstructured":"Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, et al. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res. 2002;8:712\u20137.","journal-title":"Clin Cancer Res."},{"key":"9007_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/annonc\/mdg215","volume":"14","author":"GH Schwartz","year":"2003","unstructured":"Schwartz GH, Patnaik A, Hammond LA, Rizzo J, Berg K, Von Hoff DD, et al. A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. Ann Oncol. 2003;14:775\u201382.","journal-title":"Ann Oncol."},{"key":"9007_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s002800000134","volume":"46","author":"N Pavlidis","year":"2000","unstructured":"Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol. 2000;46:167\u201371.","journal-title":"Cancer Chemother Pharmacol."},{"key":"9007_CR24","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/sj.bjc.6690232","volume":"79","author":"A Awada","year":"1999","unstructured":"Awada A, Punt CJ, Piccart MJ, Van Tellingen O, Van Manen L, Kerger J, et al. Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule. Brit J Cancer. 1999;79:1454\u201361.","journal-title":"Brit J Cancer."},{"key":"9007_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s002800050754","volume":"41","author":"O van Tellingen","year":"1998","unstructured":"van Tellingen O, Punt CJ, Awada A, Wagener DJ, Piccart MJ, Groot Y, et al. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother Pharmacol. 1998;41:377\u201384.","journal-title":"Cancer Chemother Pharmacol."},{"key":"9007_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/00000421-200206000-00022","volume":"25","author":"SN Markovic","year":"2002","unstructured":"Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, et al. Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol. 2002;25:308\u201312.","journal-title":"Am J Clin Oncol."},{"key":"9007_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/A:1006386115312","volume":"18","author":"EJ Small","year":"2000","unstructured":"Small EJ, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, et al. A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma. Invest New Drugs. 2000;18:193\u20137.","journal-title":"Invest New Drugs."}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-007-9007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-007-9007-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-007-9007-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-007-9007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:58:45Z","timestamp":1628593125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-007-9007-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["9007"],"URL":"https:\/\/doi.org\/10.1007\/s12029-007-9007-6","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"3 January 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}